INTRODUCTION
Trabeculectomy and glaucoma drainage device implantation remain the most commonly performed surgical procedures for the treatment of open angle glaucoma (OAG). Numerous studies have shown good efficacy for these surgical procedures [1] [2] [3] ; however, a high rate of complications (see Fig. 1 ) [3] has prompted the glaucoma community to search for alternative surgeries to treat OAG. During the past decade and especially the past couple of years, the interest and frequency of use of less invasive glaucoma surgeries around the world has significantly increased. An ophthalmic technology assessment by the American Academy of Ophthalmology recently reviewed the published literature about surgical glaucoma devices and procedures that have US Food and Drug Administration clearance or that were currently in phase III clinical trials in the USA as of October 2009 [4 The term micro-invasive glaucoma surgery refers to a group of surgical procedures that share five preferable qualities. The first is its ab interno microincisional approach. Ab interno glaucoma surgery through a clear corneal incision spares the conjunctiva of incisions and significant scarring, allowing future uncomplicated conjunctival surgery if needed. This approach also allows direct visualization of anatomic landmarks to optimize placement of a device or incision within the angle, and is easily combined with cataract surgery. Furthermore, a microincision facilitates the intraoperative maintenance of the anterior chamber, retention of normal ocular anatomy, minimizes changes in refractive outcome and adds to procedural safety. A second feature is a procedure that is minimally traumatic to the target tissue, with negligible disruption of normal anatomy and physiology. Devices in this category should exhibit excellent biocompatibility and ideally enhance physiologic outflow pathways. A third feature is the procedure's efficacy, which should be at least modest. Many novel procedures are initially assessed and can show promise in case series; however, ultimate proof and quantification of efficacy require a randomized clinical trial. The fourth and highly important feature of MIGS is its extremely high safety profile. These surgeries must avoid serious complications seen with other glaucoma surgeries including hypotony, choroidal effusions, suprachoroidal hemorrhage, anterior chamber shallowing, corneal decompensation, cataract formation, diplopia and bleb-related complications such as bleb dysesthesia and endophthalmitis. The fifth feature is a rapid recovery with minimal impact on the patient's quality of life. Rapidity and ease of use are important features of MIGS as well, as both glaucoma specialists and comprehensive ophthalmologists should be able to perform such surgeries with a relatively short learning curve. MIGS approaches should be straightforward and may also be easily incorporated into other procedures.
The current definition of MIGS includes three anatomical categories. The first is Schlemm's canal, by improving trabecular outflow. The second is the suprachoroidal space, by improving the uveoscleral outflow through a connection between the anterior chamber and the suprachoroid. The third is the subconjunctival space, by creating an alternative outflow pathway for aqueous humor.
The efficacy of most MIGS procedures is often modest compared to more invasive glaucoma surgeries such as trabeculectomy with mitomycin C or glaucoma drainage devices. This compromise in efficacy is balanced by an ultra-low risk profile.
KEY POINTS
Micro-invasive glaucoma surgery (MIGS) has become increasingly available and plays a different role than more invasive surgeries within the glaucoma treatment algorithm.
We define MIGS as procedures that share the following features: ab interno microincision, minimal trauma, efficacy, high safety profile, and rapid recovery.
We discuss MIGS-related future directions including the importance of the location of implantable devices, intraoperative gonioscopy, cost-effectiveness and quality-of-life studies, and randomized clinical trials. 15 (14) 11 (10) 1 (1) 2 (2) 3 (3) 2 (2) 1 (1) 10 (9) 1 (1) 2 (2) 2 (2) 5 (5) 1 (1) 5 (5) 5 (5) 5 (5) 1 (1) 2 (2) 3 (3) 1 (1) 1 (1) 1 (1) 1 (1) 42 (39) 63 (60) 1 (1) 3 ( 1 (1) 4 (4) 6 (6) 8 (8) 8 (8) 1 (1) 1 (1) 0 0 1 (1) 3 (3) 8 (8) 1 (1) 10 (10) 12 (11) 14 (13) FIGURE 1. Postoperative complications during 3 years of follow-up in the tube versus trabeculectomy study. Reproduced from [3] .
Compared to invasive glaucoma surgeries, indications for MIGS are different and typically do not include patients with very advanced disease or patients who require a very low unmedicated postoperative intraocular pressure (IOP), for example. Given the shift in efficacy and risk profile, there should also be a shift in the role of MIGS in the glaucoma treatment algorithm.
CURRENT OPTIONS
We will review the advances in the field for the following procedures during the period of annual review (2010-2011).
Glaukos micro-bypass trabecular iStent (Glaukos Corporation, Laguna Hills, CA, USA)
The iStent is manufactured from heparin-coated titanium in a single-piece design. The iStent is the smallest medical device known to be implanted in the human body (see Fig. 2a,b ). This ab interno device is implanted into Schlemm's canal using a preloaded inserter [5 && ]. Initial studies were performed with single iStent implantation, while subsequent studies assessed the effect of multiple iStents.
Fea [6] compared phacoemulsification with single iStent implantation to phacoemulsification alone in a randomized clinical trial of 36 patients with OAG. Baseline IOP and number of glaucoma medications decreased from 17.9 AE 2.6 to 14.8 AE 1.2 mmHg and from 2.0 AE 0.9 to 0.4 AE 0.7 at 15 months in the combined group, respectively. In the control group, IOP and glaucoma medications decreased from 17.3 AE 3.0 to 15.7 AE 1.1 mmHg and 1.9 AE 0.7 to 1.3 AE 1.0 [with significantly lower IOP and medication use in the combined versus control group (P ¼ 0.031 and 0.007, respectively)]. In a unique protocol design, the authors performed a washout of hypotensive medications at 15 months to minimize its potential confounding effect. The unmedicated mean IOP was 16.6 AE 3.1 mmHg and 19.2 AE 3.5 mmHg in the combined versus control group (P ¼ 0.042), respectively. There were no reported adverse events related to iStent implantation [6] . Samuelson et al. [5 && ] compared similar groups in a randomized controlled multicenter clinical trial of 240 eyes. At 1 year, 72% of eyes in the combined treatment group compared to 50% of control eyes achieved unmedicated IOP 21 mmHg or less at 1 year (P < 0.001). Stent obstruction occurred in 4% of eyes with three eyes requiring either stent repositioning or removal and one requiring laser iridoplasty within a month of surgery. Adverse events were otherwise comparable between groups [5 && ]. In safety analyses on these patients and patients from other clinical trials (n ¼ 306) with safety data through 12 months, there were no significant differences between treatment groups for best corrected visual acuity (BCVA), mean deviation and pachymetry. The most frequent postoperative adverse events were IOP increase (12%), stent obstruction (7%) and stent malposition (6%). Surgical interventions to treat malposition or obstruction did not result in loss of BCVA or other clinically important adverse events [7,8 && ]. In the longest-term follow-up study of patients who underwent combined phacoemulsification and iStent, Villalobos et al. There also appears to be benefit in implanting multiple iStents. Belovay and Ahmed [12] reported 52 patients with multiple implants (mean 2.7 AE 0.7) and showed a decrease in IOP and number of glaucoma medications from 18.7 AE 4.4 to 13.4 AE 3.6 mmHg (P < 0.001) and 2.8 AE 1.0 to 0.5 AE 0.9 (P < 0.001), respectively. A fluorophotometric study compared patients with primary open-angle glaucoma (POAG) or ocular hypertension randomized to either phacoemulsification and two iStents or phacoemulsification alone. Trabecular outflow facility increased by 275 and 46% in the treatment and control groups, respectively. IOP and number of glaucoma medications decreased from 24.2 AE 1.8 to 17.6 AE 2.8 mmHg and 1.1 AE 0.5 to 0 at 12 months in the treatment group and from 23.6 AE 1.5 to 19.8 AE 2.3 mmHg and 1.2 AE 0.7 to 0.7 AE 1.0 [with significantly lower IOP and medication use in the treatment group (P ¼ 0.04 and
Glaukos has developed a second-generation conical-shaped iStent (iStent inject) that is made out of heparin-coated titanium and designed for direct ab interno injection into Schlemm's canal through the trabecular meshwork (see Fig. 2c,d, Glaukos has also developed a third-generation iStent (iStent supra) that is made of heparin-coated polyethersulfone and a titanium sleeve. This device is designed for ab interno implantation into the suprachoroidal space (see Fig. 2f,g ). No clinical outcomes are published yet.
Hydrus Schlemm canal scaffold (Ivantis, Inc., Irvine, CA, USA)
The Hydrus device is a nitinol Schlemm canal scaffold that is open posteriorly, and contains three windows along its 8 mm length (see Fig. 3a,b) . The device is implanted through the trabecular meshwork using a manual inserter.
Ahmed et al. ] reported a 92% increase in outflow facility from 0.24 AE 0.02 to 0.46 AE 0.07 uL/min/ mmHg after implantation of the Hydrus device in nine eyes compared to no change in outflow facility in control eyes (P ¼ 0.03). Saheb et al. [18] used scanning electron microscopy (SEM) to perform a novel structural assessment of the effect of device implantation on the outer wall of Schlemm's canal. SEM images showed patency of collector channel ostia and minor changes in the outer wall of Schlemm's canal with the low profile configuration [18] . In an ocular biocompatibility study, Grierson et al. implanted the Hydrus device in the eyes of eight rabbits and the Schlemm canal of two monkeys, showing minimal inflammatory response compared to sham eyes [19] .
Ab interno trabeculectomy Trabectome (Neomedix, Inc., Tustin, CA, USA)
The Trabectome removes a strip of trabecular meshwork and inner wall of Schlemm's canal using highfrequency electrocautery. The 19.5-gauge handpiece incorporates an insulated footplate that enters Schlemm's canal through the trabecular meshwork. An irrigation port keeps the anterior chamber formed and dissipates heat, and an aspiration port is adjacent to the cautery electrode (see Fig. 4 trabeculectomy as a primary surgical procedure (n ¼ 42). They showed no difference in IOP outcome or success rates between the two groups [22 & ]. This study addresses one of the cardinal features of MIGS procedures: its ab interno and conjunctiva-sparing approach theoretically does not impact subsequent conjunctival surgery. This feature is essential to justify performing glaucoma surgeries that do not have the efficacy profile of trabeculectomy or glaucoma drainage devices.
Excimer laser trabeculostomy (Aida, Glautec AG, Nurnberg, Germany)
Excimer laser trabeculostomy (ELT) creates small holes in the trabecular meshwork and inner wall of Schlemm's canal by using energy from a quartz fiberoptic probe connected to a xenon chloride pulsed excimer laser. This probe is mounted in a stainless steel casing with an external diameter of 500 um and is beveled at 658 to aid in placement against the angle (see Fig. 5a The CyPass implant is made of polyamide material and is inserted ab interno into the suprachoroidal space through a manual inserter (see Fig. 6a-d) .
Lanchulev et al. [25 && ] reported the results of 81 eyes that underwent phacoemulsification and CyPass implantation with a mean reduction of IOP from 22.9 to 16.2 mmHg at 6 months. Postoperative adverse events were reported as shallow anterior chamber (n ¼ 1) and transient hyphema 
FUTURE DIRECTIONS
As procedures, devices and diagnostic technologies are being developed within this surgical space, a number of questions should be addressed to improve the outcome of patients undergoing MIGS.
Can we predict optimal location of device implantation?
The highest point of resistance in the conventional outflow pathway is believed to be in the juxtacanalicular component of the trabecular meshwork [27] . However, bypassing the trabecular meshwork might not be enough in all patients as the distal components of the conventional outflow pathway also offer resistance [28, 29] . A better understanding of the distribution of this resistance will help surgeons optimize the location of their surgical procedure within the circumference of the outflow pathway [30] [31] [32] . The nasal quadrant is the most common site for Schlemm canal surgery due to its easy access through clear corneal temporal incisions. This site also coincides with the area of the highest concentration of collector channels [33] . . These findings suggest that anatomical and functional assessment of conventional outflow structures distal to the trabecular meshwork can be valuable in predicting postoperative outcome. Our group suggests using areas of focal blood reflux as sites for Schlemm's canal device implantation or trabecular meshwork incision. Grieshaber et al. [35] also performed channelography by injecting fluorescein dye into Schlemm's canal using a flexible microcatheter. This technique allowed the differentiation between episcleral veins directly connected to the aqueous outflow system from ciliary veins [35] . This technique requires a conjunctival incision, which defies the cardinal features of MIGS. However, this study shows promise that further quantitative and less invasive tracer studies of the conventional outflow system can provide valuable information regarding the optimal location of Schlemm canal surgery. Furthermore, our group performs ab interno channelography through Schlemm canal devices. After implantation of the device, we inject dye through the inlet of the device to assess the anatomy of the distal outflow pathway.
Comparative outflow studies would also be valuable in predicting the optimal extent of Schlemm's canal surgery. The number of inserted devices, the length of a device or the width of a trabecular meshwork incision can all be modified to obtain the optimal increase in conventional outflow.
High-resolution imaging can provide a noninvasive method to assess the anatomy and function of the conventional outflow system. Recent work by Kagemann et al. [36 & ,37 & ] used spectral domain ocular coherence tomography (OCT) to noninvasively assess Schlemm's canal and collector channels [36 & ] and the intrascleral venous plexus [37 & ]. This study confirmed previous findings of a higher concentration of collector channels in the nasal quadrant. The same group has used a spectral domain OCT anterior segment eye scanner to show objective Doppler measurements of laminar flow using an invitro flow model of skim milk [38] . Hann et al. [39 & ] used three-dimensional micro-computed tomography to image similar structures. None of the current technologies provide both the anatomic and functional information necessary to guide surgical therapy. However, the combination and further study of above technologies may lead to a highly valuable noninvasive assessment of the conventional outflow system.
Operative technique
Current operative technique for MIGS requires direct gonioscopy, intraoperative manipulation of the microscope and the patient head, and a new angle of approach for some surgeons. With increasing use and diversity of MIGS procedures, there is interest in improving the efficiency and ease of use of angle surgery. Innovations in intraoperative gonioscopy techniques might include direct gonioscopy (without need for microscope or patient head tilt) and endoscopic or fiberoptic visualization of the angle [40] .
Cost-effectiveness and quality of life studies
As longer-term results become available for MIGS, models used for glaucoma care should be applied to assess the cost-effectiveness and quality-of-life impact of MIGS [41] [42] [43] [44] [45] . These models should incorporate the impact on quality of life related to perioperative care, the potential change in the need for glaucoma medications, the timing of further glaucoma surgery and visual function outcomes. This information is valuable to better understand the role of these procedures during dialogs with our patients, colleagues, industry collaborators and policy makers. The upfront cost and qualityof-life impact of MIGS procedures should be justified from the perspective of patients affected by these surgeries and agencies or governments covering their costs.
RANDOMIZED CLINICAL TRIALS
As has been done with the most commonly performed glaucoma surgeries today [1] [2] [3] , the role of MIGS procedures within our glaucoma treatment algorithm will be clarified as more information becomes available. Proof and quantification of effect of any surgical procedure can only be addressed with a well designed randomized clinical trial comparing the surgery to cataract surgery alone, or another procedure.
CONCLUSION
We defined MIGS as procedures that share the following features: ab interno microincision, minimal trauma, efficacy, high safety profile, and rapid recovery. There is an increasing interest and availability of MIGS procedures. It is important that this increase in surgical options is supported by a sound, peer-reviewed evidence base. Our review of the recent literature reveals that many of the MIGS devices may offer benefits to our patients with glaucoma through IOP reduction, reduced need for glaucoma medications and a high safety profile. MIGS certainly has a role within our glaucoma treatment algorithm that continues to be clarified.
